Table 3.

Senolytics treatment in age-related cardiovascular diseases.

Senolytics	Cardiovascular diseases	Dosage	Significance	Ref
D+Q	AS	Q(20mg/kg/d) for 8 weeks	Q eliminated senescent cells and alleviated AS lesions	[146]
	Aged heart	D(5mg/kg)+Q(50mg/kg) for a single dose	D+Q eliminated senescent cells and alleviated age-related cardiac dysfunction	[147]
	Aged heart	D(5mg/kg)+Q(50mg/kg) for 3 days every 3 weeks for 2 months	D+Q eliminated senescent cells and alleviated age-related cardiac dysfunction	[149]
	Aged heart/AS	D(5mg/kg)+Q(10mg/kg) once/month for 3months	D+Q eliminated senescent cells and alleviated age-related vascular disorders	[148]
Navitoclax (ABT263)	AS	100 mg/kg for a single dose	ABT263 eliminated senescent cells and reduced atherogenesis onset	[103]
	I/R	50mg/kg/d for 7 days	ABT263 eliminated senescent cells and improved cardiac function following I/R	[155]
	Aged heart	50mg/kg/d for 7 days a cycle for 2 cycles with a 1-week internal between cycle	ABT263 eliminated senescent cells and reduced hypertrophy in aged mice	[29]
	Aged heart/ MI	50mg/kg/d for 7 days a cycle for 2 cycles with a 1-week internal between cycle	ABT263 alleviated senescence in aged mice and improved heart function following MI	? [153]
	AngII	50mg/kg/d for 7 days a cycle for 2 cycles with a 1-week internal between cycle	ABT263 eliminated senescent cells and improved cardiac dysfunction induced by AngII	[154]
	PAH	10mg/kg/d for 7 days	ABT263 eliminated senescent cells and reversed established PAH	[159]

D, dasatinib; Q, quercetin; AngII, angiotensin II; PAH, pulmonary arterial hypertension; I/R, ischemia/reperfusion injury; MI, myocardial infarction; AS, atherosclerosis.